Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as „ESCC“).
The American College of Cardiology (ACC), the American Heart Association, and nine other leading medical associations today released an updated guideline for the treatment of...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they develop into tumors. The use of a...
The pharmaceutical company Grünenthal has begun the first Phase I study with its own orally available inhibitor of the voltage-gated sodium channel NaV1.8. The first healthy volunteers have already been enrolled...
